ALIGOS THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7982 USD | +3.66% |
|
-2.42% | +20.21% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,054 | 505.9 | 40.8 | 49.75 | 60.14 | - | - |
| Enterprise Value (EV) 1 | 1,054 | 505.9 | 40.8 | 49.75 | 60.14 | 60.14 | 60.14 |
| P/E ratio | -2.54 x | -3.69 x | -0.42 x | -0.49 x | -0.92 x | -0.94 x | -0.81 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 116 x | 2.93 x | 5.33 x | - | - | - |
| EV / Revenue | - | 116 x | 2.93 x | 5.33 x | - | - | - |
| EV / EBITDA | -10,772,944 x | -3,942,100 x | - | - | - | - | - |
| EV / FCF | -13,808,485 x | -4,340,084 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - | - |
| Price to Book | 4.6 x | 2.74 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 38,118 | 42,616 | 42,816 | 74,932 | 78,110 | - | - |
| Reference price 2 | 27.65 | 11.87 | 0.9529 | 0.6640 | 0.7700 | 0.7700 | 0.7700 |
| Announcement Date | 23/03/21 | 10/03/22 | 09/03/23 | 12/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 4.359 | 13.91 | 9.338 | - | - | - |
| EBITDA | - | -97.83 | -128.3 | - | - | - | - | - |
| EBIT 1 | - | -97.83 | -128.3 | -97.58 | -88.13 | -107.6 | -128.9 | -156.7 |
| Operating Margin | - | - | -2,943.82% | -701.66% | -943.75% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -108.4 | -128.2 | -95.94 | -86.88 | -107.6 | -128.9 | -156.7 |
| Net income 1 | -52.38 | -108.5 | -128.3 | -96.05 | -87.68 | -106.7 | -116 | -133.3 |
| Net margin | - | - | -2,944.07% | -690.63% | -938.95% | - | - | - |
| EPS 2 | -2.780 | -10.87 | -3.220 | -2.250 | -1.360 | -0.8350 | -0.8200 | -0.9500 |
| Free Cash Flow | - | -76.33 | -116.6 | - | - | - | - | - |
| FCF margin | - | - | -2,673.87% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 26/08/20 | 23/03/21 | 10/03/22 | 09/03/23 | 12/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.537 | 0.367 | 2.571 | 3.693 | 4.106 | 3.537 | 2.723 | 6.886 | 3.239 | 2.009 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -33.07 | -37.95 | -35.56 | -20.39 | -18.95 | -22.68 | -23.92 | -19.14 | -19.07 | -26 | -24.74 | -26.32 | -27.46 | -29.1 | -30.27 |
| Operating Margin | -2,151.46% | -10,340.05% | -1,383% | -552.21% | -461.47% | -641.28% | -878.37% | -277.97% | -588.79% | -1,294.03% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -33 | -37.77 | -35.56 | -19.88 | -18.66 | -21.84 | -22.92 | -18.03 | -18.01 | -27.92 | -24.74 | -26.32 | -27.46 | -29.1 | -30.27 |
| Net income 1 | -33.12 | -37.71 | -35.56 | -19.92 | -18.62 | -21.89 | -22.96 | -18.79 | -18.04 | -27.89 | -24.47 | -26.36 | -27.48 | -28.45 | -30.27 |
| Net margin | -2,155.11% | -10,276.29% | -1,383.2% | -539.51% | -453.51% | -618.77% | -843% | -272.89% | -556.99% | -1,388.35% | - | - | - | - | - |
| EPS 2 | -0.7800 | -0.8900 | -0.8400 | -0.4700 | -0.4400 | -0.5100 | -0.5300 | -0.4300 | -0.4100 | -0.2200 | -0.1900 | -0.2100 | -0.2150 | -0.2250 | -0.2300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 04/11/21 | 10/03/22 | 04/05/22 | 04/08/22 | 02/11/22 | 09/03/23 | 04/05/23 | 03/08/23 | 02/11/23 | 12/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -76.3 | -117 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -140% | -63.4% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -52.7% | -51.3% | - | - | - | - | - |
| Assets 1 | - | 205.9 | 250.3 | - | - | - | - | - |
| Book Value Per Share | - | 6.010 | 4.330 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | 2.06 | 0.89 | - | - | - | - | - |
| Capex / Sales | - | - | 20.46% | - | - | - | - | - |
| Announcement Date | 26/08/20 | 23/03/21 | 10/03/22 | 09/03/23 | 12/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.77
USD
Average target price
4
USD
Spread / Average Target
+419.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.21% | 60.14M | |
| +22.66% | 42.68B | |
| -3.32% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +8.10% | 24.94B | |
| -20.18% | 18.96B | |
| +29.39% | 12.3B | |
| -2.87% | 11.95B | |
| -1.63% | 11.55B |
- Stock Market
- Equities
- ALGS Stock
- Financials Aligos Therapeutics, Inc.
